Dear Editor, Since September 2012, the Middle East respiratory syndrome coronavirus (MERS-CoV) cases have been reported in more than 27 countries, and more than 2,000 cases have been confirmed in the laboratory (http://www.who.int/ emergencies /mers-cov/en/). MERS-CoV causes an acute and severe respiratory illness with a high mortality rate (~35%) in humans (Shi et al., 2017 , Zaki et al., 2012 . Neutralizing antibodies targeting the spike of MERS-CoV have been shown to be a therapeutic option for treatment of lethal disease (Agrawal et al., 2016 , Ying et al., 2014 .
In our study, we characterized a novel human monoclonal antibody (named MERS-GD27) in our human DPP4 (hDPP4) transgenic mouse model of MERS-CoV and the evaluation results showed that MERS-GD27 had preventive and therapeutic protective effects in mice before and after a lethal challenge with MERS-CoV.
The MERS-GD27 was generated from a recovered natural MERS-CoV infection patient according to the method (Smith et al., 2009) . The heavy and light chain DNA from each B cell was cloned into separate vectors. A double gene expression vector transiently transfecting into human embryonic kidney (HEK)-293FS cells was used to produce the antibody. The jetPRIME transfection reagent (Polyplustransfection ® , France) was used with equimolar amounts of heavy and light chain vector according to the standard protocol. The antibody was purified using a protein G column (GE Healthcare, USA) and protein purity was estimated by SDS-polyacrylamide gel electrophoresis and protein concentration was measured spectrophotometrically (Nanodrop Technologies Inc., USA). MERS-GD27 targeted the DPP4-binding site on the receptor-binding domain (RBD) with an IC 50 value of 0.0010 μg mL −1 in pseudovirus neutralization experiments, and showed subnanomolar affinity for the MERS-CoV S protein (equilibrium dissociation constant (K D ) equivalent to 0.775 nmol L −1 ). When neutralizing activity was tested by Plaque Reduction Neutralization Test (PRNT) using the live MERS-CoV stock (hCoV-EMC), MERS-GD27 demonstrated potent inhibitory activity against MERS-CoV infection with concentrations of 0.001 μg well −1 , and the inhibition rates were 60% ( Figure  S1 in Supporting Information).
Using the hDPP4 transgenic mice as MERS-CoV susceptible animal model (Qiu et al., 2016 , Zhao et al., 2013 , we investigated the prophylactic protective efficacy and therapeutic potential of MERS-GD27 in vivo. To accomplish this, each group (n=8) of mice was treated via the tail intravenous injection route with 5 mg kg −1 MERS-GD27 diluted in 300 μL PBS, and intranasally challenged at 24 h post-and pre-treatment with three LD 50 of MERS-CoV in a volume of 20 μL. The control group was treated with a high dose (50 mg kg −1 ) of irrelevant monoclonal antibody (anti-HA of influenza virus). Challenged mice were monitored daily for clinical manifestations (weight loss) and survival. As shown in Figure 1A , the prevention group survived at 60% showing no distinct clinical symptoms after viral infection. The therapy group survived at 40% initially showed a gradual weight loss (0%-20%) until day 11 just before starting to quickly recover (Figure 1Ai ). All surviving mice continued to recover and appeared well up to 14 dpi when the experiment was terminated (Figure 1Aii ). All MERS-CoVchallenged mice treated with irrelevant monoclonal antibody exhibited profound weight loss (>20%) and succumbed to infection with 100% mortality by day 11 p.i. (Figure 1Ai , ii).
We also investigated the lung virus titers and RNA copy in challenged mice at day 5 after virus challenge. Specifically, the lung specimens were harvested for determining viral titers of MERS-CoV by Vero E6 cell-based infectivity assay and Real time quantitative PCR assay (qRT-PCR). As shown in Figure 1Bi , the lung viral titers among mice treated with MERS-GD27 pre-or post-viral challenge were significantly lower (P<0.001) compared to control group. In addition, viral RNA loads among mice treated with MERS-GD27 preor post-viral challenge were also significantly lower than those in the control group (Figure 1Bii ). These data indicated that MERS-GD27 conferred significant protection for mice when administered pre-or post-viral challenge.
MERS-GD27 could effectively protect in both prophylactic and postexposure settings in vivo. Thus, MERS-GD27 was highly promising as a potent inhibitor for urgent prophylaxis in adjunctive treatment for patients infected with MERS-CoV. We noted that passively transferred with 5 mg kg −1 of MERS-GD27 to mice 24 h prior to challenge with three LD 50 of MERS-CoV resulted in 60% protection against lethality. Although using 5 mg kg −1 MERS-GD27 as a prophylaxis was suboptimal to completely neutralize viral infection, the protective effect was obviously presented compared to control groups, especially to the recovery of bodyweight loss and the reduction of viral loads, as shown in Figure 1 . The therapeutic efficacy of MERS-GD27 was similar to the prophylactic studies, administration of MERS-GD27 at a concentration of 5 mg kg −1 at 24 h after MERSCoV challenge provided 40% protection, against infectioninduced lethality, accompanied by reduced viral loads (both infectious virus and viral RNA) within the lungs. These data demonstrated that MERS-GD27 was an effective therapeutic agent for MERS-CoV infection.
Taken together, these results indicated that the MERS-CoV specific human monoclonal antibody could be highly effective as prophylactic or therapeutic modalities in protecting transgenic mice against MERS-CoV infection. In the future, more exploration and research need to be performed on Figure 1 The functional verification of MERS-GD27 in MERS-CoV susceptible mice. A, Prophylactic and therapeutic efficacy of MERS-GD27 in protecting susceptible mice against lethal dose MERS-CoV challenge. Challenged mice were monitored daily for the weight loss (i) and accumulated mortality (ii), expressed as percent (%) body weight and survival rate, respectively. B, Treatment with MERS-GD27 significantly inhibited MERS-CoV infection within the lungs. Lung specimens collected at day 5 after viral challenge were processed for assessing the viral titers by using both Vero E6-based infectivity assay and qRT-PCR targeting N3 gene of MERS-CoV, and expressed as log 10 TCID 50 /g and log 10 TCID 50 equivalent (eq.)/g, respectively. (i) Prophylactic and therapeutic efficacy of MERS-GD27 treatment in reducing the lung titers of infectious virus. (ii) Prophylactic and therapeutic efficacy of MERS-GD27 in reducing the titers of viral RNA. The data were representative of at least two independently conducted assays using the same samples. Data were presented as mean±standard error (SE). *, ** and ***, P<0.001 as determined by using Student's t test. Figure S1 The functional verification of MERS-GD27 in vitro.
SUPPORTING INFORMATION
The supporting information is available online at http://life.scichina.com and https://link.springer.com. The supporting materials are published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains entirely with the authors.
